RecruitingPhase 2NCT07393672

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms


Sponsor

Washington State University

Enrollment

104 participants

Start Date

Feb 11, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.


Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 60 Years

Inclusion Criteria9

  • designated female at birth
  • years of age
  • able to give informed consent (no intellectual disability)
  • stable pharmacotherapeutic regimen, no change in the past 3 months
  • abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months
  • abstinent for supplements, don't add any supplements (no changes in past 3 months)
  • own a smartphone
  • have access to Zoom on a secure, stable internet connection
  • perimenopausal or menopausal

Exclusion Criteria11

  • currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
  • severe depression, neurovegetative symptoms, or current suicidality
  • psychosis or family history of psychosis
  • pregnant or breastfeeding
  • chemotherapy
  • hypotension
  • drug testing for work or other reasons
  • illicit drug use in past 3 months (cannabis not illicit)
  • heavy alcohol use (4 drinks more than 4x/week)
  • international/air travel planned for more than one week in the next 3 months
  • cocounut allergy

Interventions

DRUGHemp-derived cannabinoids

Participants will be administered a legal product with hemp-derived cannabinoids and terpenes.

DRUGPlacebo

Participants will be administered a placebo


Locations(1)

Washington State University, Dept of Psychology

Pullman, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07393672


Related Trials